Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Common Equity (2016 - 2026)

Phibro Animal Health has reported Common Equity over the past 13 years, most recently at $332.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 34.67% year-over-year to $332.4 million; the TTM value through Dec 2025 reached $332.4 million, up 34.67%, while the annual FY2025 figure was $285.7 million, 11.32% up from the prior year.
  • Common Equity for Q4 2025 was $332.4 million at Phibro Animal Health, up from $311.7 million in the prior quarter.
  • Over five years, Common Equity peaked at $332.4 million in Q4 2025 and troughed at $215.9 million in Q1 2021.
  • A 5-year average of $265.7 million and a median of $266.5 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: dropped 9.16% in 2024 and later skyrocketed 34.67% in 2025.
  • Year by year, Common Equity stood at $239.3 million in 2021, then increased by 12.15% to $268.4 million in 2022, then increased by 0.91% to $270.8 million in 2023, then fell by 8.86% to $246.8 million in 2024, then surged by 34.67% to $332.4 million in 2025.
  • Business Quant data shows Common Equity for PAHC at $332.4 million in Q4 2025, $311.7 million in Q3 2025, and $285.7 million in Q2 2025.